BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23087083)

  • 21. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
    Zhuang SH; Burnstein KL
    Endocrinology; 1998 Mar; 139(3):1197-207. PubMed ID: 9492054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered VDR-mediated transcriptional activity in prostate cancer stroma.
    Hidalgo AA; Paredes R; Garcia VM; Flynn G; Johnson CS; Trump DL; Onate SA
    J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):731-6. PubMed ID: 17368189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells.
    Essa S; Denzer N; Mahlknecht U; Klein R; Collnot EM; Tilgen W; Reichrath J
    J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):110-3. PubMed ID: 20153427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
    Kim S; Shevde NK; Pike JW
    J Bone Miner Res; 2005 Feb; 20(2):305-17. PubMed ID: 15647825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines.
    Essa S; Reichrath S; Mahlknecht U; Montenarh M; Vogt T; Reichrath J
    Anticancer Res; 2012 Jan; 32(1):383-9. PubMed ID: 22213330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer.
    Khor TO; Fuentes F; Shu L; Paredes-Gonzalez X; Yang AY; Liu Y; Smiraglia DJ; Yegnasubramanian S; Nelson WG; Kong AN
    Cancer Prev Res (Phila); 2014 Dec; 7(12):1186-97. PubMed ID: 25266896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
    Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
    Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic regulation of BMP2 by 1,25-dihydroxyvitamin D3 through DNA methylation and histone modification.
    Fu B; Wang H; Wang J; Barouhas I; Liu W; Shuboy A; Bushinsky DA; Zhou D; Favus MJ
    PLoS One; 2013; 8(4):e61423. PubMed ID: 23620751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor.
    Dunlop TW; Väisänen S; Frank C; Molnár F; Sinkkonen L; Carlberg C
    J Mol Biol; 2005 Jun; 349(2):248-60. PubMed ID: 15890193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VDR primary targets by genome-wide transcriptional profiling.
    Goeman F; De Nicola F; D'Onorio De Meo P; Pallocca M; Elmi B; Castrignanò T; Pesole G; Strano S; Blandino G; Fanciulli M; Muti P
    J Steroid Biochem Mol Biol; 2014 Sep; 143():348-56. PubMed ID: 24726990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer.
    Luo W; Karpf AR; Deeb KK; Muindi JR; Morrison CD; Johnson CS; Trump DL
    Cancer Res; 2010 Jul; 70(14):5953-62. PubMed ID: 20587525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of VDR-responsive gene signatures in breast cancer cells.
    Towsend K; Trevino V; Falciani F; Stewart PM; Hewison M; Campbell MJ
    Oncology; 2006; 71(1-2):111-23. PubMed ID: 17377416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic repression of transcription by the Vitamin D3 receptor in prostate cancer cells.
    Gommersall LM; Khanim FL; Peehl DM; Doherty AH; Campbell MJ
    J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):251-6. PubMed ID: 15225780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines.
    Zhuang SH; Schwartz GG; Cameron D; Burnstein KL
    Mol Cell Endocrinol; 1997 Jan; 126(1):83-90. PubMed ID: 9027366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1,25-Dihydroxyvitamin D3 induces differentiation of a retinoic acid-resistant acute promyelocytic leukemia cell line (UF-1) associated with expression of p21(WAF1/CIP1) and p27(KIP1).
    Muto A; Kizaki M; Yamato K; Kawai Y; Kamata-Matsushita M; Ueno H; Ohguchi M; Nishihara T; Koeffler HP; Ikeda Y
    Blood; 1999 Apr; 93(7):2225-33. PubMed ID: 10090931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticancer activity of VDR-coregulator inhibitor PS121912.
    Sidhu PS; Teske K; Feleke B; Yuan NY; Guthrie ML; Fernstrum GB; Vyas ND; Han L; Preston J; Bogart JW; Silvaggi NR; Cook JM; Singh RK; Bikle DD; Arnold LA
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):787-98. PubMed ID: 25107568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1Alpha,25(OH)2D3-induced transrepression by vitamin D receptor through E-box-type elements in the human parathyroid hormone gene promoter.
    Kim MS; Fujiki R; Murayama A; Kitagawa H; Yamaoka K; Yamamoto Y; Mihara M; Takeyama K; Kato S
    Mol Endocrinol; 2007 Feb; 21(2):334-42. PubMed ID: 17095575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells.
    Akutsu N; Lin R; Bastien Y; Bestawros A; Enepekides DJ; Black MJ; White JH
    Mol Endocrinol; 2001 Jul; 15(7):1127-39. PubMed ID: 11435613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ETV4 promotes late development of prostatic intraepithelial neoplasia and cell proliferation through direct and p53-mediated downregulation of p21.
    Cosi I; Pellecchia A; De Lorenzo E; Torre E; Sica M; Nesi G; Notaro R; De Angioletti M
    J Hematol Oncol; 2020 Aug; 13(1):112. PubMed ID: 32791988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.
    Lopez SM; Agoulnik AI; Zhang M; Peterson LE; Suarez E; Gandarillas GA; Frolov A; Li R; Rajapakshe K; Coarfa C; Ittmann MM; Weigel NL; Agoulnik IU
    Clin Cancer Res; 2016 Aug; 22(15):3937-49. PubMed ID: 26968201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.